Axio Biosolutions
Axio, a pioneering Indian medtech firm, manufactures advanced wound care products with USFDA clearance.
Founded
2008Axio, a pioneering Indian medtech firm, manufactures advanced wound care products with USFDA clearance.
Axio Biosolutions, founded in India, is a medtech R&D and manufacturing company dedicated to advanced surgical and wound care solutions. The company’s core mission is to reduce mortality from traumatic injuries through innovative medical products. Axio's flagship product, Axiostat, is a CE-approved hemostatic dressing based on a patented 100% chitosan platform, designed to control life-threatening bleeding. Axio Biosolutions has the distinction of being the first Indian company to receive USFDA clearance for a wound care product, positioning itself as a leader in the global wound care market.
Notable figures associated with Axio Biosolutions include its pioneering founders and key investors who have supported its growth. The company has achieved significant milestones, including the USFDA clearance and widespread adoption of Axiostat in various medical settings. Axio's impact is profound, as its products are instrumental in saving lives by effectively managing traumatic bleeding and enhancing surgical outcomes. Through continuous innovation and adherence to high regulatory standards, Axio Biosolutions is making substantial contributions to the field of medical technology.
Companies similar to Axio Biosolutions include Chitogen, Medcura, Cresilon and Beeken Biomedical.
Axio Biosolutions was founded in 2008.
Axio Biosolutions' headquarters is located in Cambridge, MA, US.
Axio Biosolutions' most recent funding round was for $6M (USD) in July 2021.
As of Jul 27, 2021, Axio Biosolutions has disclosed funding of $21M (USD). Undisclosed round amounts are excluded.
Axio Biosolutions has 175 employees as of Feb 4, 2024.
Beeken Biomedical
